Insomnia After the COVID-19 Pandemic

The aim of this study is to investigate the levels of insomnia 3 months after (T2) the strict physical distancing government initiated physical distancing protocols related to the COVID-19 pandemic (T1). The study also aims to investigate how predictors measured after and before the COVID-19 pandemic are associated with sleep problems at T2.

Study Overview

• Status: Unknown
• Conditions: Depression; Insomnia; Sleep; Anxiety; Metacognitive Beliefs

Detailed Description

Hypothesis/Research Questions H1: What is the level of mental insomnia following three months of strict mitigation strategies (i.e., physical distancing) in the general adult population during the COVID-19 pandemic? The mean level of insomnia will be benchmarked against the mean level of insomnia in similar pre-pandemic samples.

Exploratory: What is the level of insomnia in different demographic subgroups.

H2: The level of metacognition, strategies, worry about job and economy, health-anxiety and physical activity at T2 will predict insomnia at T2, beyond and above, age, gender, and education.

Exploratory: Does metacognition, strategies, worry about job and economy, health-anxiety and physical activity at T1 predict Insomnia at T2, beyond and above psychiatric diagnosis, age, gender, and education and predictors at T2?

Statistical analysis:

A hierarchical regression analysis will be conducted using BIS as the dependent variable. In the first step stable characteristics (control variables) will be included: age, gender and education. In the second step metacognition, strategies, worry about job and economy, health-anxiety and physical activity at T2 will be included. Part-correlation will be reported for step 2, presenting the effect size of the predictors on insomnia. In the third step, anxiety and depression at T2 will be included as control for the variables at the next step. In the last step metacognition, strategies, worry about job and economy, health-anxiety and physical activity, at T1 will be included.

Multicollinearity and other statistical assumptions will be checked. Multicollinearity will be assessed with common guidelines (VIF < 5 and Tolerance > 0.2; Hocking, 2003; O'Brian, 2007). Descriptive statistics with frequency tables including N, means and SDs and other standard descriptive statistics will be used to examine the level of insomnia. Subgroup differences will be examined with chi-squared statistics or other statistic based on the characteristics of the data (e.g. skewness).

All analysis and questions addressed in the forthcoming paper that are not pre-specificd in this pre-registered protocol will be defined as exploratory.

Sensitivity analyses and random subsample replications of the main finding will be conducted following selection of a random sample of participants that ensure a proportional ratio between the collected sample and the adult population in Norway

Measures On the CAS1 four items were combined into the subscale "positive metacognition", four items were combined into the subscale "negative metacognition", and 8 items were combined into the subscale strategies (Nordahl & Wells, 2019). Physical activity was measured with a single item. Worry about job and economy consisted of two items. Health anxiety consists of four items.

Possible transformations:

All variables will be assessed in their original and validated format as is recommended practice, as long as this is possible with regards to statistical assumptions underlying the pre-defined analyses (i.e., multiple regression). However, if this is not possible with regards to the statistical assumptions behind the analyses, transformation (e.g., square root or log-transformations) may be needed to apply interval-based methods, alternatively the use of non-parametric tests.

Inference criteria Given the large sample size in this study, the investigators pre-define their significance level: p < 0.01 to determine significance.

Sample size:

The present study is part of a larger project with the part aiming to investigate predictors of sleep trough regression analysis, and the second part aiming to examine directional relations among specific symptoms and their centrality through network analysis. Thus, the power calculations are based on power required for network analysis.

Following power analysis guidelines by Fried & Cramer (2017), it is recommended that the number of participants are three times larger than the number of estimated parameters. However, more conservative recommendations by Roscoe (1975) for multivariate research, recommends sample size that is ten times larger than the number of estimated parameters. Thus, following these two approaches respectively, between 1584 to 5280 participants are required. Data will be collected for three weeks, and participants are based on a representative and random sample of Norwegian adults, randomly selected and provided equal opportunity to partake in the study, providing digital consent.

Eligibility criteria:

Inclusion Criteria:

• Eligible participants are all adults including those of 18 years and above,
• Who are currently living in Norway and thus experiencing identical NPIs, and
• Who had provided digital consent to partake in the study.

Exclusion Criteria:

• Children and adolescents (individuals below 18) Adults not residing in Norway during the measurement period

Missing data:

The TSD system (Services for Sensitive Data), a platform used in Norway to store person-sensitive data verifies participants officially through a kind of national ID number to give them full right to withdraw their data at any time, following the European GDPR (General Data Protection Regulation) laws. Accordingly, participants are allowed to withdraw their own data at any time. The survey includes mandatory fields of response. Participation is voluntarily, and withdrawal of provided data is possible at any moment. We do not expect participants to withdraw their data and thus expect no missing data. However, if participants do withdraw their data, we will conduct state-of-art missing data analyses and investigate whether data is missing at random.

Exploratory:

Questions addressed in the future paper which is not pre-specified will be defined as exploratory.

• Study Type: Observational
• Enrollment (Anticipated): 5000

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: N/A
• Genders Eligible for Study: All

• Sampling Method: Probability Sample

Study Population

The general population in Norway.

Description

Inclusion Criteria:

• Eligible participants are all adults including those of 18 years and above,
• Who are currently living in Norway and thus experiencing identical NPIs, and
• Who had provided digital consent to partake in the study.

Exclusion Criteria:

• Children and adolescents (individuals below 18) Adults not residing in Norway during the measurement period

Study Plan

How is the study designed?

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Bergen insomnia scale (BIS)	Bergen Insomnia scale is developed as a short measure of insomnia consisting of six items measured on a 8-point Likert-scale (Pallesen et al., 2008)	Data is set to be collected starting from 22th of June. The data collection period will last no longer than three weeks depending on the response to the questionnaire

Collaborators and Investigators

• Sponsor: University of Oslo
• Collaborators: Modum Bad

Study record dates

Study Major Dates

• Study Start (ANTICIPATED): June 22, 2020
• Primary Completion (ANTICIPATED): July 13, 2020
• Study Completion (ANTICIPATED): July 13, 2020

Study Registration Dates

• First Submitted: June 19, 2020
• First Submitted That Met QC Criteria: June 22, 2020
• First Posted (ACTUAL): June 23, 2020

Study Record Updates

• Last Update Posted (ACTUAL): June 23, 2020
• Last Update Submitted That Met QC Criteria: June 22, 2020
• Last Verified: June 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Nervous System Diseases; Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Sleep Disorders, Intrinsic; Dyssomnias; Sleep Wake Disorders; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Sleep Initiation and Maintenance Disorders
• Other Study ID Numbers: REK125510 (7)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No